Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID IM045-1018  |   NCT06782490

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Summary

  • Phase 2
  • Male and Female Gender icon
  • 18-70
    Age Range
  • 47
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Participants must have a multiple sclerosis (MS) diagnosis.
    1. Participants must have a history of spasticity due to MS for at least 6 months prior to Visit 1.
      1. Participants must have a Modified Ashworth Scale (mAS) score ≥2 in each of 2 muscle groups (at least one muscle group in the leg, excluding ankle plantar flexors) at Visit 1.
        1. Participants must have an Expanded Disability Status Scale (EDSS) score 3.0-6.5 at Visit 1.

          Exclusion Criteria

          Exclusion Criteria Icon
          • Participants must not have any concomitant disease or disorder that has symptoms of spasticity or that may influence the participant's level of spasticity.
            1. Participants must not have an acute MS exacerbation/relapse requiring treatment or alteration in disease modifying drug dose within 3 months of Visit 1 or Visit 2.
              1. Participants must not have a history of any substance abuse disorder as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Diagnostic Criteria for Drug and Alcohol Abuse.
                1. Participants must not be currently taking a medication for spasticity that cannot be discontinued and washed out by Visit 2.
                  1. Participants must not have used FAAH/MAGL inhibitor medication or any cannabinoid-related products (including cannabis, cannabidiol (CBD), or tetrahydrocannabinol (THC)) within 30 days prior to Visit 1.
                    Additional Information *
                    • Other protocol-defined Inclusion/Exclusion criteria apply.

                      Treatment Options

                      Study Arms

                      ASSIGNED INTERVENTION

                      Study Arms

                      Experimental: Administration of BMS-986368 Dose A

                      ASSIGNED INTERVENTION
                      • Drug: BMS-986368

                      Study Arms

                      Experimental: Administration of BMS-986368 Dose B

                      ASSIGNED INTERVENTION
                      • Drug: BMS-986368

                      Study Arms

                      Experimental: Administration of BMS-986368 Dose C

                      ASSIGNED INTERVENTION
                      • Drug: BMS-986368

                      Study Arms

                      Placebo Comparator: Placebo

                      ASSIGNED INTERVENTION
                      • Drug: Placebo
                      Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                      Check Your Eligibility
                      Answer some questions about Your health to see if you may match to this trial
                      Match to a Trial
                      If you are a match, click on the study to see the list of study site locations
                      Select a Study Site Location
                      Select a study site location that is convenient for you
                      Register
                      Provide your contact details for the study site to connect with you.

                      Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you